09/2019 Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium. Isabelle Ray-Coquard, Ioana Braicu, Regina Berger, Sven Mahner, Jalid Sehouli, Eric Pujade-Lauraine, Philippe Alexandre Cassier, Ute Martha Moll, Hanno Ulmer, Karin Leunen, Alain Gustave Zeimet, Christian Marth, Ignace Vergote and Nicole Concin on behalf of the entire GANNET53 Consortium (18 Partner Institutions in Europe). Front Oncol. September 2019, Volume 9, Article 832; doi: 10.3389/fonc.2019.00832; Publication
11/2018 Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates. Maritschnegg E, Heinzl N, Wilson S, Deycmar S, Niebuhr M, Klameth L, Holzer B, Koziel K, Concin N, Zeillinger R. Anal Chem. 2018 Nov 20;90(22):13273-13279. doi: 10.1021/acs.analchem.8b02373.Publication
11/2016 Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitoticDNA fragmentation in ovarian cancer cells. Cell Death and Differentiation (2016), 1–17, Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M. doi: 10.1038/cdd.2016.124. Publication

Presentations to a Scientific Audience

09/2019 21st European Society of Gynaecological Oncology (ESGO) Congress, Athens, Greece; Abstract and presentation by Dr Adriaan Vanderstichele, KU Leuven: “TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC) — a prospective translational analysis of the phase II GANNET53 clinical trial”. Winner: Best Oral Communications / Late-Breaking Abstracts - Ovarian Cancer Presentation
09/2019 21st European Society of Gynaecological Oncology (ESGO) Congress, Athens, Greece; Presentation by Prof. Nicole Concin, Innsbruck Medical University: “DNA repair interfering therapies beyond PARPi”.
06/2019 2019 ASCO Annual Meeting, Chicago, USA; Abstract and poster: “EUDARIO/ENGOTov-48: A European multicenter randomized Phase II trial on the combination of the HSP90 inhibitor Ganetespib with Carboplatin followed by maintenance treatment with Niraparib (+/- Ganetespib) compared to platinum-based combination-chemotherapy followed by Niraparib in relapsed platinum-sensitive ovarian cancer patients”
09/2018 12th Biennial Ovarian Cancer Research Symposium, Seattle/Washington/USA; Abstract presented by Nicole Heinzl (Medical University of Vienna): “Identification of p53 Prions as an Independent Prognostic Marker for Survival in High-Grade Serous Ovarian Cancer” Link
06/2018 2018 ASCO Annual Meeting, Chicago, USA, Abstract and poster: “Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high–‐grade serous, high–‐grade endometrioid, or undifferentiated, platinum–‐resistant epithelial ovarian, fallopian tube or primary peritoneal cancer”
11/2017 20th European Society of Gynaecological Oncology (ESGO) Congress, Vienna, Austria; Poster presented: “IDetection and Characterization of P53 Prions in High-Grade Serous Ovarian Cancer”
11/2017 20th European Society of Gynaecological Oncology (ESGO) Congress, Vienna, Austria; Poster presented: “P53 PROTEINS ARE ABLE TO EXHIBIT PRION-LIKE BEHAVIOUR - A STUDY TO ESTABLISH RELIABLE DETECTION TECHNIQUES IN OVARIAN TUMOURS”
09/2017 21. Onkologischer Alpengipfel Loas, Austria; Presentation held by Dr. Katarzyna Koziel: “p53 PROTEIN IS ABLE TO EXHIBIT PRION-LIKE BEHAVIOUR”
11/2016 AMP 2016 Annual Meeting, Charlotte, NC / USA; Abstract and Poster: “The use of a hybridisation-based NGS enrichment panel for the confident identification of a broad range of low frequency variants from as little as 50ng of challenging clinical research FFPE samples.”
05/2016 Seventh Gynaecological Cancer Academy in Copenhagen/Denmark; Lecture held by Prof Nicole Concin: Title: “Molecular basis of ovarian cancer and therapeutic implications: p53”
01/2016 19. Onkologischer Alpengipfel; 10.-12.9.2015; 40 Jahre translationale Forschung an der Frauenklinik Innsbruck, 40 Jahre Labor für Klinische Biochemie; Wissenschaftliche Rück- und Ausblicke; Presentation of the GANNET53 Clinical Trial
10/2015 1st Ovarian Cancer Academy, 4th - 7th October 2015, Cluj-Napoca, Romania; Presentation held by Nicole Concin: “p53: targeting ovarian cancer at its roots”
10/2015 9th International Meeting of the European Society of Gynaecological Oncology (ESGO 2015) in Nice, France, October 24-27, 2015; Presentation held by Nicole Concin in the session “New Targeted Treatments in Gynaecological Cancers”; Title: “Targeting HSP-90 in gynaecological cancer”
05/2015 2015 ASCO Meeting, Chicago, Illinois; Abstract and poster presented by Prof. Isabelle Ray-Coquard (P7): “Part I of GANNET53: A multicentre phase I/II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer”.
04/2015 8th International Charité-Mayo-Conference: Updates in Gynecology: A Global Perspective; Berlin/Germany, Lecture held by Prof.Nicole Concin: “p53: targeting ovarian cancer at its roots”
04/2015 OR - Institute of Oncology Research, Bellinzona, Switzerland, Lecture held by Prof Nicole Concin: “Targeting p53: attacking ovarian cancer at the roots”
03/2015 9e Rencontres Scientifiques du GINECO in Paris/France; lecture held by Nicole Concin (P1); Title: “Targeting p53: attacking ovarian cancer cell at the roots”
09/2014 Fourth Gynaecological cancer academy (GCA) Workshop in Frankfurt/Germany, Lecture held by Nicole Concin: “Inhibiting the gain-of-function of mutated p53”
06/2014 16th International p53 Workshop, Stockholm, Sweden. Lecture held by Ute M. Moll (P11/UMG-GOE): “Exploiting tumor cell addiction to mutant p53 by pharmacological inhibition of the HSP90 chaperone axis in knocking mouse moddels”; Link:
10/2013 17th Oncologic Summit Loas, Tyrol, Austria. Lecture: “The tumor-promoting aspect of mutated p53 - therapeutic implications” Program
10/2013 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, UK. Poster presented on the GANNET53 Phase I trial


06/2018 Interview given by Prof. Concin regarding the EUDARIO trial to be conducted in the framework of the GANNET53 project for the online magazine Krebs:hilfe! during the ASCO Annual Meeting 2018, Chicago, USA Link:;
07/2016 Press release by Angle PLC / UK on its cooperation with the GANNET53 consortium regarding sample analysing. 28.07.2016 Press release ;
01/2016 Article in MED INN Magazin der Medizinischen Universität Innsbruck: “Das mutierte Wächter-Gen [The mutated guardian of the genome].” (in German) Article;
10/2015 Article in FORUM MEDIZIN. Die Zeitung für medizinische Forschung, Lehre und Krankenversorgung. Supplement to Tiroler Tageszeitung [Tyrolean daily newspaper]: “Eierstockkrebs: Innovative Therapie. Erste Ergebnisse bei EU-Projekt GANNET53. [Ovarian cancer: innovative therapy. First results from EU project GANNET53].” (in German) Article
08/2015 Press release by Medical University of Innsbruck “Innovative Behandlung von Eierstockkrebs: Erste Ergebnisse bei EU-Projekt GANNET53” [Innovative Treatment of Ovarian Cancer: First Results in the GANNET53 EU project] 17.08.2015}
08/2015 Article in Der STANDARD [Austrian daily newspaper]: “Eierstockkrebs: Therapie für Frauen, die sonst chancenlos sind“ [Ovarian cancer: a therapy for woman with rare changes]; (in German) Link
06/2015 Press release by Synta Pharmaceuticals: “First Patient Enrolled in Phase 2 Portion of GANNET53 Study of Ganetespib in Ovarian Cancer” Press release
04/2015 Article published in Jatros HÄMATOLOGIE & ONKOLOGIE 4/15, p.230ff: “Innovative Therapie des Ovarialkarzinoms. p53-basierte Therapieansätze finden Einzug in die Klinik.“ Article
04/2015 Article in Gyn-Aktiv [Austrian gynaecological journal], issue 02/2015: “Status aktueller AGO Studien: GANNET53 [Status of ongoing AGO trials]“
12/2014 Article in TIROLER BAUERNZEITUNG [Tyrolean farmers’ journal], issue 50: “Frauen und Krebs – ein höchst aktuelles Thema“ [women and cancer – a most topical subject] (in German) Article
12/2014 Article in DER MEDICUS, Journal der Hochschülerschaft an der Medizinischen Universität Innsbruck [journal of the students association at Innsbruck Medical University]; interview with Nicole Concin; issue 03/2014 (in German) Article
11/2014 Forum Land [lecture series organised by the Tyrolean Farmers’ Association]; lecture held by Nicole Concin in Pettna, Tyrol, Austria: “Neue Therapien bei Eierstockkrebs”[new therapies for ovarian cancer]
07/2014 Article in DIE PRESSE [Austrian daily newspaper]: “Krebsgen unter der Lupe” [cancer gene under the microscope] (in German) Article
05/2014 Article in GYN-AKTIV [Austrian gynaecological journal], issue 02/2014: “Auswahl aktueller AGO Studien” [Selected AGO trials] (in German) Article
05/2014 Article in TIROLER TAGESZEITUNG [Austrian daily newspaper]: „Mit neuem Medikament den stillen Krebs aufhalten” [Stop the silent cancer with new drug]
05/2014 Article in ECHO – Tirols erstes Nachrichtenmagazin [Tyrolean monthly magazine], issue 05/2014 (in German): “Innovative Wege” [innovative approaches] Article
04/2014 Special supplement in DER STANDARD [Austrian daily newspaper]: “FFG Forschungsefolge” [Austrian Research Promotion Agency: achievements in research] (in German)
04/2014 Article in Annual Report 2013 of the Austrian Research Promotion Agency FFG; presentation of the GANNET53 project
01/2014 Press release by SYNTA PHARMACEUTICALS Press release
12/2013 Article in the online magazine JOURNAL ONKOLOGIE”[oncologic journal]; Link
12/2013 Article in DER STANDARD [Austrian daily newspaper] (in German): “Rasterfandung in Krebszellen” [Dragnet investigation in cancer cells] (in German) Article
11/2013 Press information by STANDORTAGENTUR TIROL [Public agency of the Province of Tyrol/Austria for economic and scientific affairs] (in German) Press information
11/2013 Tiroler Standort Lunch in Vienna, Austria [event organized by the province of Tyrol to foster Tyrol as as econcomic and scientific location]; Nicole Concin presents the GANNET53 project: “GANNET53 - Eierstockkrebs innovativ therapieren“ [GANNET53 – innovative therapy for ovarian cancer] Program
11/2013 Press release by the GANNET53 CONSORTIUM (in German) Press release

Project Meetings

02/2019 7th GANNET53 Consortium Meeting, Rome, Italy
01/2018 6th GANNET53 Consortium Meeting, Berlin, Germany
01/2017 5th GANNET53 Consortium Meeting, Innsbruck, Austria
01/2016 4th GANNET53 Consortium Meeting, Frankfurt, Germany
01/2015 3rd GANNET53 Consortium Meeting, Leuven, Belgium.
04/2014 2nd GANNET53 Consortium Meeting - Kick-off of Phase I Trial, Lyon, France.
10/2013 GANNET53 Kick-off Meeting, Frankfurt, Germany. Agenda